Kirin Pharma To Close Three Of Four R&D Sites In Japan
This article was originally published in PharmAsia News
Executive Summary
Kirin Pharma of Japan says it will close all but one of its R&D sites within the next three years. The firm, a subsidiary of Kirin Holdings, has four such sites in the Gunma Prefecture employing about 200 researchers. The company said the workers would be reassigned as it sells the closing facilities. Kirin R&D work is to be done in conjunction with another subsidiary, Kyowa Hakko Kogyo, after a merger scheduled for October. (Click here for more - a subscription may be required